Kornimate/medical-research-clean huggingface dataset:
stress-echography in hereditary haemorrhagic telangiectasia patient with hepatic involvement

Conditions: Hereditary Hemorrhagic Telangiectasia; Rendu Osler Disease

Summary: the hepatic involvement of hht (hereditary haemorrhagic telangiectasia) disease is characterised by the formation of arterio-sus-hepatic shunts which lead to dilatation of the hepatic artery and may result in high output heart failure. this evolves silently for long-standing period from left ventricular cavities dilatation to advanced heart failure with post-capillary pulmonary hypertension (ph) (more rarely pre-capillary), and its evolution is poorly understood. the specific treatment options for hht disease are either the use of anti-angiogenic therapy (bevacizumab) or liver transplantation. as rest echocardiography can only detect advanced cases or heart failure with rest ph, the investigators speculate that exercise echocardiography can provide additional information in patients without rest ph. the hypothesis is that an exaggerated pulmonary pressure increase during exercise may precede the occurrence of rest ph in the course of the disease. it could identify patients with substantial heart failure at an earlier stage and may facilitate the access to liver transplantation. these parameters have never been studied in this context and it seems interesting to evaluate them in this pilot study. the investigators hypothesise that hht (hereditary haemorrhagic telangiectasia) patients with hepatic involvement and cardiac high output will have significantly greater and/or earlier elevation of exercise pulmonary arterial pressures than those with normal cardiac output.


Eligibility criteria:
inclusion criteria: * hht patient \> 18 yo * hepatic involvement (hepatic artery diameter \> 6mm) * patient having received the information and signed the informed consent form * patient affiliated to a social security scheme or beneficiaries of a similar scheme exclusion criteria: * haemoglobin \< 90 g/l * active infection * atrial fibrillation permanent or persistent * known cardiopathy * pregnant or breastfeeding woman (by questioning) * adult subject to a legal protection measure (guardianship) * participation in another clinical trial that may interfere with the proposed trial (investigator judgment) * patient physically unable to pedal * patient with pulmonary arteriovenous malformations awaiting embolization * patient treated with beta-blockers secondary exclusion criteria verified on rest ultrasound * pah (pulmonary arterial hypertension) at rest (vmax \> 2.8 m/sec) * inability to obtain a stream of it at rest * patient with atrial fibrillation (af)

Keywords: hht stress echography pulmonary arterial pressures
neurofeedback to aid vets' memory

Conditions: Mild Cognitive Impairment

Summary: military deployment is associated with increased risk of mild cognitive impairment (mci). combat stress related memory deficits has been well documented. mild cognitive impairment such as memory deficits are the most common and earliest symptoms of alzheimer's disease and related dementia (adrd). the complaints about declined memory are common in healthy and cognitively intact civilian older adults, but less understood in aging veterans. brain training strategies to enhance cognitive skills and especially memory processes are unmet needs in aging veterans who are at additional risk for mci induced by adrd. since currently there is no effective drug treatment to stop cognitive decline, non-invasive brain training to boost memory functions in older veterans is an increasingly attractive option to attenuating decline in memory.

the proposed project is poised to investigate state-of-art neurofeedback (nf; biofeedback of brain activity) training for self-modulation of neural plasticity to boost memory performance in veterans. the recent advance of nf with brian-computer interface (bci) has provided a novel way to examine brain functions and plasticity. thus far, there have been limited applications that have developed effective experimental and clinical paradigms for rehabilitation in veterans. historically, brainwave patterns during memory task performance have been analysed offline, a methodology which does not allow real-time nf modulation and training. the central hypothesis guiding this research is that optimal memory-related brainwave patterns of a veteran can be trained. the online nf allows maximization of brainwave patterns associated with healthier memory states. the development of efficient nf paradigms to augment memory performance is an important first step for the application of this nonpharmacologic intervention to improve combat veterans' memory functions and potential for treating mci due to mild tbi or pain. the pilot work will start with wider range of veterans using state-of-the-art wearable wireless brain-computer interface headset, which is affordable and can be easily set up in vamcs and eventually in remote assessment settings. this innovative, cognitive neuroscience based, nonpharmacologic intervention serves to revolutionize the diagnosis and treatment of combat veterans who are at risk for degenerative dementia.

Eligibility criteria:
inclusion criteria: * veterans age 60 and older exclusion criteria: * veterans diagnosed with ptsd, epilepsy schizophrenia, or use benzodiazapines

Keywords: neurofeedback amnestic mci wireless eeg bluegrass memory test working memory
impact of yogotherapeutics on chronic pains' patients

Conditions: Chronic Pain

Summary: in a context where yoga is more and more popularized in france and in europe, and where yogatherapy (as complementary medicine) begins to make its place in the care of patients in french hospitals, it seems interesting to study the impact of yoga in the chronic pain patient treated in a specific pain consultation by this non-pharmacological approach, and accessible.

yoga is a discipline that has its origins in india for nearly 5,000 years, and which aims to bring physical, mental and spiritual well-being through postures, stretching, breathing exercises and meditation. non-invasive and having very few side effects, this approach allows the practitioner to reclaim their body, to know themselves better, to accept their limits, to respect them and to empower themselves in their care and pathology. more and more studies are now looking at the positive effect of yoga whether it is on stress by demonstrating the drop in cortisol in participants, or on the reduction of symptoms of depression, improvement of immune function, or pain. to our knowledge, no study of the impact of yoga for analgesic treatment has been carried out in france. through this retrospective study, the investigators wish to demonstrate a reduction in pain and / or an improvement in the quality of life.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old, * seen in consultation for chronic pain with implementation of yogatherapy, exclusion criteria: * patient \< 18 years old, * no indication for yogatherapy treatment (severe cognitive disorder / major unbalanced psychological disorder), * trauma pathology and / or acute fracture in progress, * patient refusal to participate.

Keywords: chronic pain yogatherapeutics
a study of ly2189265 in japanese participants with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: this was a 52-week, multicenter, non-randomized, open-label, phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (oam).


Eligibility criteria:
inclusion criteria: * participants who have had a diagnosis of type 2 diabetes mellitus before screening * participants who have been taking su (glibenclamide, gliclazide, glimepiride), bg, tzd, a-gi or glinides monotherapy for at least 3 months before screening and have been on a stable dose for at least 8 weeks before screening * participants must have a qualifying hba1c value of 7.0% to 11.0% at screening * participants who have a body mass index (bmi) of 18.5 to 35.0 kilograms per meter squared (kg/m\^2) exclusion criteria: * participants who have a diagnosis of type 1 diabetes * participants who have previously been treated with any other glucagon-like peptide-1 (glp-1) analog within the 3 months before screening * participants who are currently taking insulin or have had previous insulin treatment within the 3 months before screening * participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, as determined by the investigator. participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening * participants who have self or family history of medullary c-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (mtc)

Keywords: type 2 diabetes mellitus oral antihyperglycemic medications long-term safety glp 1 glucagon like peptide 1
study of disc anaesthesia for the preoperative diagnosis of chronic lower back pain

Conditions: Low Back Pain

Summary: the primary objective of this study is to document and compare diagnostic test results and procedure safety in subjects undergoing both functional anaesthetic discographytm (f.a.d.) and provocative discography (pd) and determine the appropriateness of the f.a.d. procedure data collection script for use in a larger clinical trial.


Eligibility criteria:
inclusion criteria: * age \> 21. * chronic axial low back pain without radicular pain for \> six months, not responding to at least three months of non-surgical management under the direction of a physician. * one or two discs at l5/s1, l4/l5 or l3/l4 with abnormal findings by mri, including any of the following: loss of disc hydration, loss of disc height, high intensity zone (hiz), modic changes at adjacent vertebral endplates, or herniation without nerve root compression. * subject states that he/she is willing to undergo lumbar spinal fusion, disc replacement, or other definitive treatment if eventual diagnosis supports such treatment. * physician believes that discography is clinically indicated for the purpose of surgical decision-making for the subject. * pre-treatment low back pain by numerical rating scale (nrs) score \> 4 (measured as average in last 24 hours on a 0-10 scale). * pre-treatment oswestry disability index (odi) \> 40 (0 - 100 scale). * subject states availability for all study visits. * subject is able to understand the risks and benefits of participating in the study and provides written informed consent. exclusion criteria: * known osteoporosis or osteopenia, metabolic bone disorder, or history of chronic steroid use (the equivalent of 7.5 milligrams of daily prednisone use for \> 6 months). * suspected painful disc degeneration (based on clinical examination and mri findings) outside of l5/s1, l4/l5 or l3/l4 levels. * mri shows disc abnormalities (listed in inclusion criteria #3) at all 3 lower lumbar discs (l3/l4, l4/l5 and l5/s1). * abnormal neurologic exam attributable to lumbar disc disease, herniation, or lumbar stenosis. * back, buttock or pelvic pain suspected to be due to spinal stenosis, spinal fractures, infection, cancer, facet arthropathy or other hip or pelvis pathology. * schmorl's node or endplate disruption evident on mri at l5/s1, l4/l5, or l3/l4. * medical history, physical examination or radiographic evidence (e.g., disc height too narrow) to suggest that either pd or f.a.d. may not be technically feasible. * any previous lumbar spine fusion or disc replacement. * more than grade 1 spondylolisthesis as assessed by x-ray or mri. * significant clinical comorbidity that may potentially interfere with data collection or follow-up (e.g., dementia, severe comorbid illness). * history of major depression, psychosis or somatization disorder, or panic disorder. * allergy to any materials used in pd or f.a.d. devices, contrast, lidocaine, or bupivacaine. * any evidence of disc or systemic infection. * pregnant or child-bearing potential and not currently on adequate birth control method.

Keywords: low back pain, degenerative disc disease
development of a digital tool for the individualization of speech therapy care for premature newborns

Conditions: Premature Birth

Summary: the study concerns the creation and implementation of a digital tool presenting the various orofacial stimuli that can be offered to premature newborns. this app is intended for parents, to allow them to play a more active role in their child's care, and provide them with special time with their child. the notion of pleasure is very important to us, and it's vital to help parents rediscover this feeling with their child. different profiles will be created to individualize our recommendations, facilitate the understanding of orofacial stimuli, make them more concrete than drawings, and provide care adapted to each patient and improve the development of newborns through more regular orofacial stimulation.

two groups will be formed: group a - control: receiving the speech therapy currently in place in the department. group b - experimental: will receive the same care as the first group, plus access to the videos and the introduction of early orofacial stimulation. group b: first, an initial assessment will be performed in speech-language pathology of the oro-myofunctional and oral functions of the newborn. this will determine which orofacial solicitations to give to the baby and create in the patient's profile. parents will be trained in orofacial stimulation and will be coached during the first sessions. when parents are ready, access will be given to their personal space on the application. appointments will be scheduled to remodel the treatment if necessary. sucking (ecepab), feeding (pibbs) and behavioural (edin) abilities will be assessed. parents will be asked to fill out a questionnaire about their feelings.

Eligibility criteria:
inclusion criteria: * child born prematurely before 29 weeks of amenorrhea (sa). * alive for minimum 24h. * holders of parental authority who have been informed of the study and have not objected. exclusion criteria: * child born after 29 weeks of amenorrhea. * with a genetic or severe neurological pathology or withdrawal syndrome. * with a vital prognosis. * whose family home is too far from the service.
brain oxygenation-ii

Conditions: Cerebral Hypoxia

Summary: the brain oxygenation-ii study (box-ii) is a phase-ii, multicenter, single-arm clinical trial evaluating interventions based on near-infrared spectroscopy (nirs) monitoring of cerebral oxygen saturation in extremely premature infants. enrolled infants will follow a treatment guideline to maintain cerebral oxygen saturation in a target range within the first 72 hours of life. the primary outcomes will include interventions used to maintain cerebral saturation in target range, rates of cerebral hypoxia and systemic hypoxia, and a composite of death or severe brain injury detected on term-equivalent magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * infants born with postmenstrual age less than 28 weeks * signed informed consent exclusion criteria: * missing written parental informed consent * decision not to conduct full intensive care support * no possibility to place cerebral nirs oximeter within six hours after birth * skin integrity insufficient to allow for sensor placement as deemed by a clinician
non-invasive prenatal diagnostic validation study

Conditions: Chromosome 13 Aneuploidy; Chromosome 18 Aneuploidy; Chromosome 21 Aneuploidy; Sex Chromosome Aberrations; Other Microdeletions

Summary: the primary purpose of this study is to collect maternal blood samples from pregnant women to develop a non-invasive prenatal diagnostic test based on fetal dna isolated from maternal blood.

the investigators will seek to enroll subjects to collect the following types of samples: * up to 2,000 maternal blood samples along with their corresponding paternal blood, buccal or saliva samples (1,000 required for final analysis). * up to 200 maternal blood samples from carrying a fetus with a confirmed chromosomal abnormality or genetic disorder, along with their corresponding paternal blood, buccal or saliva samples (50 required for final analysis). for women who opted for termination, a genetic sample of the fetus may also be collected. * up to 1,000 buccal or saliva samples from paternal grandfathers and/or the biological father's brothers. * up to 1,000 cord, buccal or saliva samples from the born children. * up to 40 blood samples (20 non-pregnant females and 20 males) from healthy volunteers (20 required for final analysis) * up to 400 blood samples from women undergoing d\&c procedure following a miscarriage along with corresponding paternal blood (or buccal or saliva samples) (200 required for final analysis).

Eligibility criteria:
inclusion criteria: * pregnant women who volunteer to donate blood sample during the first -, second- and/or third trimester * the biological father of the child (or the father's brother and/or father) has to be at least 18 years of age and consent to his blood, buccal, or saliva collection. * pregnant women whose fetus was diagnosed with a chromosomal abnormality or genetic disorder by either amniocentesis or chorionic villus sampling who volunteer to donate a blood sample. * pregnant women who volunteer to donate a blood sample after their spontaneous miscarriage prior to undergoing d\&c procedure and who choose to utilize natera's commercial products of conception molecular karyotyping service. * healthy volunteers (non-pregnant female and male) who volunteer to donate their blood sample. * umbilical cord blood or cheek swab/saliva samples from born children o pregnant women who have participated in donating a blood sample during their pregnancy have the option to donate either an umbilical cord blood sample after child delivery, or a cheek swab or saliva sample from the born child using natera's home kit. exclusion criteria: * women carrying multiples

Keywords: down syndrome trisomy 13 trisomy 18 microdeletions pregnancy non-invasive
safety and efficacy of the ureca cto device

Conditions: Peripheral Vascular Disease

Summary: clinical study to investigate the safety and the efficacy of the ureca cto device during recanalization and mechanical re-entry into the true lumen after passing the occlusions/calcifications (chronic total occlusions) in the peripheral vasculature.

peripheral arterial disease (pad) restricts blood supply to the lower limbs. the disease causes obstructions that can affect blood vessels in both the proximal and distal regions. when these vessel obstructions exist for more than 3- 6 months they are classed as chronic total occlusions. without sufficient collateral formation this can lead to to chronic limb-treatening ischemia (clti), which is characterized by chronic pain and tissue loss. without revascularization this frequently leads to amputation. the purpose of this clinical study is to investigate the safety and the efficacy of the ureca cto device during recanalization and mechanical re-entry into the true lumen after passing the occlusions/calcifications (chronic total occlusions) in the peripheral vasculature.

Eligibility criteria:
inclusion criteria: * subject must be \>= 18 and \<= 85 years old * clinically diagnosed for endovascular treatment of peripheral vascular disease and chronic total occlusion in the iliac artery, superficial femoral artery or in the proximal popliteal artery determined by duplex, cta, mra and/or dsa. * patient has been assessed by an independent vascular surgeon and an interventional radiologist. * written and signed informed consent exclusion criteria: * 1. concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy; 2. severe infection or soft tissue loss that may preclude any meaningful attempt at limb salvage; 3. known or suspected allergies or contraindications to contrast agents; 4. any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimal participation in the study; 5. the subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study; 6. patient unable to give consent; 7. pregnant and breastfeeding women; 8. patients who recently suffered from a stroke and/or a myocardial infarct (within 2 months) 9. patients with an uncontrollable diabetes; 10. severe intercurrent illness that, in the opinion of the investigator, may put the subject at risk when participating in the study 11. patients with hypercoagulopathy; 12. stent in place in the to be treated artery
pulse rate and breathing rate accuracy

Conditions: Pulse Rate and Breathing Rate

Summary: the purpose of this study is to conduct a breathing rate and pulse rate accuracy validation comparing the nuralogix amc-sdk to the reference devices, an fda cleared end tidal carbon dioxide monitor (ge datex-ohmeda) and a standard ecg (ge datex-ohmeda) derived heart rate reference. this will be done by manually scoring the collected waveform for data analysis.


Eligibility criteria:
inclusion criteria: * participants must have the ability to understand and provide written informed consent or have legally authorized representative consent to participate * participant must be 18 to 81 years of age (≥ 18 age to \< 82) * participant must be willing and able to comply with study procedures and duration * participants or legally authorized representative must be able to read or write in english exclusion criteria: * participants who refuse or are unable to provide to sign an informed written consent for study * participants evaluated by the investigator and clinical staff and found to be medically - unsuitable or have self-reported health conditions that are currently unstable as identified in the health assessment form and health screening * compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor region of interest (roi) which would limit the ability to test roi needed for the study. tattoo in the optical path which would limit the ability to test roi needed for the study. (note: certain malformations may still allow participants to participate if the condition is noted and would not affect the particular areas utilized.) * participants with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ecg electrodes, or other medical sensors (self- reported) * other known health condition, should be considered upon disclosure in health assessment form